Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Jorgensen, Andrea L ^a   FitzGerald, Richard J ^a   Oyee, James ^a   Pirmohamed, Munir ^a   Williamson, Paula R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ARTICLE; ASIAN; BLEEDING; CYP2C9 GENE; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; EPISTAXIS; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENOTYPE; HEMATOMA; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MELENA; META ANALYSIS; PATIENT COMPLIANCE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; VKORC1 GENE;

ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEMORRHAGE; HUMANS; INHERITANCE PATTERNS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; PATIENT COMPLIANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84865604759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044064     Document Type: Article

References (143)

1. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323: 1505-1511.
2. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342: 1255-1262.
3. Stroke Prevention in Atrial Fibrillation Investigators, (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348: 633-638.
4. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, et al. (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18: 349-355.
5. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327: 1406-1412.
6. Burns M, (1999) Management of narrow therapeutic index drugs. J Thromb Thrombolysis 7: 137-143.
7. Wadelius M, Pirmohamed M, (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7: 99-111.
8. FDA (2007) FDA Approves Updated Warfarin (Coumadin) Prescribing Information.
9. Flockhart DA, O'Kane D, Williams MS, Watson MS, Gage B, et al. (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10: 139-150.
10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, et al. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S.
11. Jorgensen AL, Williamson PR, (2008) Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 27: 6547-6569.
12. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J, (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34: 1319-1328.
13. Salanti G, Higgins JP, (2008) Meta-analysis of genetic association studies under different inheritance models using data reported as merged genotypes. Stat Med 27: 764-777.
14. Sanderson S, Emery J, Higgins J, (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7: 97-104.
15. McClain MR, Palomaki GE, Piper M, Haddow JE, (2008) A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 10: 89-98.
16. Liang R, Wang C, Zhao H, Huang J, Hu D, et al. (2012) Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thrombosis Research 130: 38-44.
17. Kealey C, Chen Z, Christie J, Thorn CF, Whitehead AS, et al. (2007) Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 8: 217-225.
18. Fukuda T, Tanabe T, Ohno M, Tougou K, Fujio Y, et al. (2006) Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes. Clin Pharmacol Ther 80: 553-554.
19. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, et al. (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103: 2630-2635.
20. Kosaki K, Yamaghishi C, Sato R, Semejima H, Fuijita H, et al. (2006) 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr Cardiol 27: 685-688.
21. Bertola JP, Mazoyer E, Bergmann JF, Drouet L, Simoneau G, et al. (2003) Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thrombosis Research 109: 287-291.
22. D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, et al. (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89: 1510-1516.
23. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, et al. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110: 1511-1515.
24. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, et al. (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 53: 1199-1205.
25. Ogg MS, Brennan P, Meade T, Humphries SE, (1999) CYP2C9*3 allelic variant and bleeding complications.[comment]. Lancet 354: 1124.
26. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine 352: 2285-2293.
27. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333.
28. Gonzalez Della Valle A, Khakharia S, Glueck CJ, Taveras N, Wang P, et al. (2009) VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study. Clin Orthop Relat Res 467: 1773-1780.
29. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG, (2000) Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128: 281-285.
30. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, et al. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5: 389-392.
31. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, et al. (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91: 87-94.
32. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287: 1690-1698.
33. Lee S, Kim JM, Chung CS, Cho KJ, Kim JH, et al. (2003) Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients. Archives of Pharmacal Research 26: 967-972.
34. Lee VW, You JH, Lee KK, Chau TS, Waye MM, et al. (2005) Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis 20: 33-38.
35. Moridani M, Fu L, Selby R, Yun F, Sukovic T, et al. (2006) Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clinical Biochemistry 39: 606-612.
36. Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, et al. (2007) Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clinical Pharmacology & Therapeutics 81: 742-747.
37. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, et al. (2002) The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. Journal of the American College of Surgeons 194: 267-273.
38. Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, et al. (2005) In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics & Genomics 15: 475-481.
39. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, et al. (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95: 205-211.
40. Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, et al. (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis & Haemostasis 93: 700-705.
41. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, et al. (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5: 262-270.
42. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, et al. (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121: 23-34.
43. Topic E, Stefanovic M, Samardzija M, Topic E, Stefanovic M, et al. (2004) Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clinical Chemistry & Laboratory Medicine 42: 72-78.
44. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, et al. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116: 2563-2570.
45. Bodin L, Perdu J, Diry M, Horellou MH, Loriot MA, (2008) Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 6: 1436-1439.
46. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112: 1022-1027.
47. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331.
48. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R, (2008) CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 64: 9-15.
49. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL, (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 100: 229-239.
50. Miao L, Yang J, Huang C, Shen Z, (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63: 1135-1141.
51. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, et al. (2007) Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8: 1535-1544.
52. Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, et al. (2007) Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 8: 713-719.
53. Ngow H, Teh LK, Langmia IM, Lee WL, Harun R, et al. (2008) Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study. Xenobiotica 38: 641-651.
54. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, et al. (2008) Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 84: 722-728.
55. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, et al. (2004) CYP2C9 genetic polymorphisms and warfarin. Clinical & Applied Thrombosis/Hemostasis 10: 149-154.
56. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, et al. (2008) Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clinica Chimica Acta 396: 76-79.
57. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, et al. (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84: 83-89.
58. Wu AH, Wang P, Smith A, Haller C, Drake K, et al. (2008) Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9: 169-178.
59. Yin T, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, et al. (2008) No association between vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) and the variability of warfarin dose requirement in a Japanese patient population. Thrombosis Research 122: 179-184.
60. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10: 261-266.
61. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, et al. (2009) Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 19: 226-234.
62. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, et al. (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113: 784-792.
63. Jorgensen AL, Al-Zubiedi S, Zhang JE, Keniry A, Hanson A, et al. (2009) Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 19: 800-812.
64. Aithal GP, Day CP, Kesteven PJ, Daly AK, (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717-719.
65. Chern HD, Ueng TH, Fu YP, Cheng CW, Chern H-D, et al. (2006) CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clinica Chimica Acta 367: 108-113.
66. Gan GG, Phipps ME, Ku CS, Teh A, Sangkar V, et al. (2004) Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose. International Journal of Hematology 80: 295-296.
67. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, et al. (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14: 539-547.
68. Kohnke H, Sorlin K, Granath G, Wadelius M, (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 61: 381-388.
69. Linder MW, Looney S, Adams JE, 3rd, Johnson N, Antonino-Green D, et al (2002) Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. Journal of Thrombosis & Thrombolysis 14: 227-232.
70. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, et al. (2001) Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 70: 159-164.
71. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y, et al. (2007) Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clinical Therapeutics 29: 427-437.
72. Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL, (2006) Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 4: 1723-1729.
73. Pchelina SN, Sirotkina OV, Taraskina AE, Vavilova TV, Shwarzman AL, et al. (2005) The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thrombosis Research 115: 199-203.
74. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM, (2004) CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 75: 198-203.
75. Spreafico M, Peyvandi F, Pizzotti D, Moia M, Mannucci PM, (2003) Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. Journal of Thrombosis & Haemostasis 1: 2252-2253.
76. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, et al. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clinical Pharmacology & Therapeutics 73: 253-263.
77. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Molecular Genetics 14: 1745-1751.
78. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, et al. (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clinical Pharmacology & Therapeutics 76: 210-219.
79. Caraco Y, Blotnick S, Muszkat M, (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83: 460-470.
80. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, et al. (2008) Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 65: 260-264.
81. Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, et al. (2008) Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 6: 1655-1662.
82. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, et al. (2008) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9: 511-526.
83. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9: 1445-1458.
84. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, et al. (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83: 312-321.
85. Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, et al. (2008) VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 64: 889-894.
86. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, et al. (2008) Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 84: 332-339.
87. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, et al. (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358: 999-1008.
88. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, et al. (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112: 1013-1021.
89. Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, et al. (2004) Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thrombosis & Haemostasis 91: 1123-1128.
90. Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, et al. (2005) Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.[see comment]. Clinical Medicine & Research 3: 207-213.
91. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, et al. (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79: 291-302.
92. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649.
93. King BP, Khan TI, Aithal GP, Kamali F, Daly AK, (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14: 813-822.
94. Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.[see comment]. Blood 98: 2584-2587.
95. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A, et al. (2005) Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clinical Pharmacology & Therapeutics 78: 540-550.
96. Taube J, Halsall D, Baglin T, (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96: 1816-1819.
97. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, et al. (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113: 3925-3930.
98. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, et al. (2006) Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79: 197-205.
99. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, et al. (2004) 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103: 3055-3057.
100. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, et al. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenetics & Genomics 16: 101-110.
101. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, et al. (2006) A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80: 346-355.
102. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, et al. (2005) CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology & Therapeutics 77: 353-364.
103. Verstuyft C, Robert A, Morin S, Loriot MA, Flahault A, et al. (2003) Genetic and environmental risk factors for oral anticoagulant overdose. European Journal of Clinical Pharmacology 58: 739-745.
104. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, et al. (2008) Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 8: 53-60.
105. Li T, Lange LA, Li X, Susswein L, Bryant B, et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. Journal of Medical Genetics 43: 740-744.
106. Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, et al. (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Journal of Thrombosis & Thrombolysis 22: 191-197.
107. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, et al. (2005) Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clinical Pharmacology & Therapeutics 77: 365-372.
108. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, et al. (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology & Therapeutics 72: 702-710.
109. Tanira MO, Al-Mukhaini MK, Al-Hinai AT, Al Balushi KA, Ahmed IS, et al. (2007) Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genetics 10: 32-37.
110. Yildirim H, Tamer L, Sucu N, Atik U, (2008) The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement. Med Princ Pract 17: 464-467.
111. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, et al. (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109: 2477-2480.
112. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, et al. (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics Journal 5: 193-202.
113. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, et al. (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51: 249-253.
114. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, et al. (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75: 204-212.
115. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, et al. (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clinical Medicine & Research 3: 137-145.
116. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, et al. (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84: 775-778.
117. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, et al. (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4: 40-48.
118. Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, et al. (2009) Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics 19: 103-112.
119. Cho HJ, Sohn KH, Park HM, Lee KH, Choi B, et al. (2007) Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8: 329-337.
120. Samardzija M, Topic E, Stefanovic M, Zibar L, Samardzija G, et al. (2008) Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy. Coll Antropol 32: 557-564.
121. Hatch E, Wynne H, Avery P, Wadelius M, Kamali F, (2008) Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. J Thromb Haemost 6: 1038-1040.
122. Michaud V, Vanier MC, Brouillette D, Roy D, Verret L, et al. (2008) Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 83: 740-748.
123. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5: e1000433.
124. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, et al. (2007) Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 5: 8-16.
125. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V, (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95: 782-787.
126. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, et al. (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thrombosis & Haemostasis 93: 23-26.
127. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, et al. (2006) VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 80: 169-178.
128. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, et al. (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120: 181-186.
129. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP, (2006) An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 16: 705-711.
130. Little J, Higgins JPT (2006) The HuGENet™ HuGE Review Handbook, version 1.0. Available: http://www.hugenet.org.uk/resources/handbook.php. Accessed 3 August 2012.
131. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
132. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6: e22.
133. Jorgensen AL, Pirmohamed M, Tudur Smith C, Williamson PR Influence of CYP2C9, VKORC1 and environmental factors on patient response to warfarin: a HuGENet systematic review and meta-analysis protocol. HuGENet Protocol. Available: http://hugenet.org.uk/resources/protocols/WarfarinMAprotocol.pdf. Accessed 3 August 2012.
134. Higgins JPT, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.1. Wiley.672 p.
135. Whitehead A (2003) Meta-Analysis of Controlled Clinical Trials: Wiley.
136. Lunn DJ, Thomas A, Best N, Spiegelhalter D, (2000) WinBUGS- A Bayesian modelling framework: Concepts, structure, and extensibility. Statistics and Computing 10: 325-337.
137. Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, et al. (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22: 191-197.
138. Khan T, Wynne H, Wood P, Torrance A, Hankey C, et al. (2004) Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 124: 348-354.
139. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106-4112.
140. Gage B, Eby C, Johnson J, Deych E, Rieder M, et al. (2008) Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clin Pharmacol Ther.Sep 84(3): 326-31.
141. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, et al. (2005) Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics & Genomics 15: 687-691.
142. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, et al. (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124: 970-979.
143. Koefoed BG, Gullov AL, Petersen P, (1995) Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and Design. J Thromb Thrombolysis 2: 125-130.